Migraine Connect
  • Saved

made a Post

4yr
Summary of the 64th Annual Scientific Meeting of The American Headache Society

The 64th annual scientific meeting of the American Headache Society (AHS) provided attendees with many opportunities to learn about the latest advancements in diagnosing and treating headaches. In this post-conference wrap-up report, we review some of the meeting highlights. Click the image above to access.


  • Saved

made a Post

4yr
Summary of the 64th Annual Scientific Meeting of The American Headache Society

The 64th annual scientific meeting of the American Headache Society (AHS) provided attendees with many opportunities to learn about the latest advancements in diagnosing and treating headaches. In this post-conference wrap-up report, we review some of the meeting highlights. Click the image above to access.

  • Saved

made a Post

4yr
Summary of the 64th Annual Scientific Meeting of The American Headache Society

The 64th annual scientific meeting of the American Headache Society (AHS) provided attendees with many opportunities to learn about the latest advancements in diagnosing and treating headaches. In this post-conference wrap-up report, we review some of the meeting highlights. Click the image above to access.


  • Saved

made a Post

4yr
Summary of the 64th Annual Scientific Meeting of The American Headache Society

The 64th annual scientific meeting of the American Headache Society (AHS) provided attendees with many opportunities to learn about the latest advancements in diagnosing and treating headaches. In this post-conference wrap-up report, we review some of the meeting highlights. Click the image above to access.


  • Saved

4yr
Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study - Neurological Sciences

Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study - Neurological Sciences

Source : https://link.springer.com/article/10.1007/s10072-022-06190-w

Previous studies reported a positive effect of anti-CGRP monoclonal antibodies (mAbs) in migraine prevention, either in over (O65) and under (U65) 65-year-aged patients. The aim of our study was to...


Relevance: Previous studies reported a positive effect of anti-CGRP monoclonal antibodies (mAbs) in migraine prevention, either in over (O65) and under (U65) 65-year-aged patients. The aim of our study was to evaluate and compare real-life efficacy and safety of mAbs between young and elder migraine patients.